A one-year trial of tiotropium Respimat ® plus usual therapy in COPD patients

In this randomised double-blind study, patients ≥40 years old with COPD, a smoking history of ≥10 pack-years, a pre-bronchodilator FEV 1 of ≤60% predicted and an FEV 1/FVC of ≤70% received tiotropium 5 μg or placebo via Respimat ® inhaler once daily for 48 weeks. Other medications were permitted exc...

Full description

Saved in:

Bibliographic Details
Published in:	Respiratory medicine Vol. 104; no. 10; pp. 1460 - 1472
Main Authors:	Bateman, E.D., Tashkin, D., Siafakas, N., Dahl, R., Towse, L., Massey, D., Pavia, D., Zhong, N.S.
Format:	Journal Article
Language:	English
Published:	Kidlington Elsevier Ltd 01.10.2010 Elsevier Elsevier Limited
Subjects:	Aged Biological and medical sciences Bronchodilator Agents - administration & dosage Bronchodilator Agents - adverse effects Chronic obstructive pulmonary disease, asthma Clinical trials COPD Disease Progression Double-Blind Method Drug therapy Exacerbation Female Forced Expiratory Volume - drug effects Forced Expiratory Volume - physiology Humans Male Medical sciences Patient Compliance Pharmaceutical industry Pneumology Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - mortality Pulmonary Disease, Chronic Obstructive - physiopathology Pulmonary/Respiratory Quality of life Respiratory Function Tests Scopolamine Derivatives - administration & dosage Scopolamine Derivatives - adverse effects Smoking - physiopathology Spirometry Tiotropium Tiotropium Bromide Exacerbation Spirometry Tiotropium COPD Human Lung disease Respiratory disease Tiotropium bromide Exploration Chronic Lung function Treatment Bronchus disease Chronic obstructive pulmonary disease Obstructive pulmonary disease Pneumology
ISSN:	0954-6111, 1532-3064, 1532-3064
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!